Nafazatrom

Nafazatrom is a pyrazolinone-derived lipoxygenase inhibitor that elevates endogenous prostacyclin (PGI2) levels, exhibiting antithrombotic effects and experimental anticancer activity. It has been studied in research models for its role in reducing arrhythmias following cardiac injury and in modulating eicosanoid pathways in vitro.